Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Gilead Sciences Q1 2026: Executive Equity, Patent Cliffs, M&A, & Market Strategy

Gilead Sciences shares executive equity awards, updated financials and a roadmap for next‑gen antivirals, patent strategy, and M&A moves to stay ahead of pricing pressures and rivals.

Lisa Martinez

07/05/2026, 07:24

4 minutes to read

Novo Nordisk Q1 2026 Earnings: Wegovy’s $2.1B Impact, Market Access & Growth Strategy

Novo Nordisk’s Q1 2026 earnings show how Wegovy’s $2.1 B launch, savvy pricing, and a diversified pipeline keep growth strong amid insulin competition, currency swings and patent cliffs—insightful for pharma investors.

Lisa Martinez

06/05/2026, 19:41

5 minutes to read

Johnson & Johnson Q1 2026 Update: Stelara’s Oral Peptide, IBD Wins, & Strong Financial Turnaround

Johnson & Johnson’s Q1 2026 update shows Stelara’s oral peptide boost, IBD phase‑3 wins and strong financial turnaround, positioning J&J for long‑term growth in psoriasis and gut biotech.

Lisa Martinez

06/05/2026, 19:21

4 minutes to read

Pfizer’s Earnings Outlook: Growth, Patents, and M&A Prospects

Pfizer’s next earnings report shows modest quarterly gains but a sharp FY uptick driven by new obesity and rare‑disease drugs, highlighting patent cliffs, market‑access tactics, and M&A opportunities.

Lisa Martinez

05/05/2026, 13:49

3 minutes to read

Thermo Fisher Q1 2026: Solid Growth, Strong Cash & Strategic Expansion in Diagnostics

Thermo Fisher’s Q1 2026 results show modest revenue gains, steady profitability, and strategic investments in toxicology and genomic cancer testing—offering investors a disciplined, growth‑oriented outlook for the biotech diagnostics market.

Lisa Martinez

03/05/2026, 12:29

4 minutes to read

United Therapeutics Insider Trades Show No Strategic Shift, Focus on Future Growth

Insider trades by UTH CEO Martina Rothblatt show no strategic shift, but the company faces patent cliffs for Macitentan. Learn how UTH plans pricing, pipeline, and M&A to protect growth and compete in pulmonary hypertension.

Lisa Martinez

02/05/2026, 08:02

5 minutes to read

Pfizer’s ELREXFIO Shows PFS Breakthrough in MagnetisMM‑5 Phase‑3 Trial

Pfizer’s interim MagnetisMM‑5 data show ELREXFIO improves progression‑free survival in RRMM, promising a premium price and strong market impact.

Lisa Martinez

01/05/2026, 03:00

4 minutes to read

Agilent’s RF Strategy Mirrors Pharma’s Market‑Access Playbook—Driving Growth & Innovation

Agilent Technologies’ latest report shows how high‑margin RF modules fuel growth and offer a blueprint for pharma and biotech firms tackling market access, patent cliffs, and M&A in fast‑moving sectors.

Lisa Martinez

30/04/2026, 16:15

4 minutes to read

Merck KGaA Accelerates Advanced‑Therapy Growth with Remepy Digital Partnership and M&A Outlook

Merck KGaA’s latest earnings reveal steady €20 bn revenues and €4 bn net income, while a strategic partnership with Remepy blends biologics with AI‑driven digital therapeutics, positioning the company to navigate patent cliffs, secure payer value, a…

Lisa Martinez

30/04/2026, 01:30

4 minutes to read

West Pharmaceutical Services Surge: Strong Buy, Rising EPS, and $3‑4B Injection Device Opportunity

West Pharmaceutical Services surges after strong Q1 earnings, citing cost‑efficient manufacturing, global expansion and new injection device tech—read why analysts see a “strong buy” trend.

Lisa Martinez

29/04/2026, 14:51

4 minutes to read

Newer articles